TITLE

Clinical and Ultrasonographic Characteristics of Breast Metastases from Extramammary Malignancies

AUTHOR(S)
Chun-Nan Yeh; Cheng-Hung Lin; Miin-Fu Chen
PUB. DATE
April 2004
SOURCE
American Surgeon;Apr2004, Vol. 70 Issue 4, p287
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Breast metastases from extramammary malignancies are uncommon, constituting about 2 per cent of all breast tumors. Breast metastasis may be confused with primary benign or malignant neoplasm of the breast. An accurate diagnosis of breast metastasis is important because the treatment and outcome of primary and secondary malignancies of the breast are completely different. The clinical features of 15 patients with breast metastases from extramammary malignancies, excluding lymphoma, between 1982 and 2001 were retrospectively reviewed. There were 2 male and 13 female patients, with ages ranging from 16 to 73 years (median, 48 years). Primary tumors in the 15 cases were 3 hepatocellular carcinomas, 2 gastric carcinomas, 2 malignant melanomas, 1 colon carcinoma, 1 lung adenocarcinoma, 1 ovarian carcinoma, 1 uterine leiomyosarcoma, 1 nasopharyngeal carcinoma, 1 esophageal squamous carcinoma, 1 embryonal rhabodomyosarcoma, and 1 cervical carcinoma. Bilateral breast involvement was observed in two patients. A solitary lesion was evident in 13 patients, with 6 in the right breast and 7 in the left. The interval between diagnosis of primary cancer and the discovery of breast metastasis ranged from 0 to 144 months (median, 12 months). The follow-up period of the primary tumor ranged from 7 months to 156 months (median, 17 months). Breast metastases were associated with disseminated metastatic disease in 14 of the 15 patients. Fourteen of the patients died within a year of breast metastasis diagnosis; median survival was 4 months. Breast metastases from extramammary malignancy are infrequent. Virtually any malignancy can metastasize to the breast. Breast metastasis usually indicates disseminated metastatic disease and a poor prognosis.
ACCESSION #
12753340

 

Related Articles

  • Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics. Critchley-Thorne, Rebecca J.; Miller, Steven M.; Taylor, D. Lansing; Lingle, Wilma L. // Combinatorial Chemistry & High Throughput Screening;Nov2009, Vol. 12 Issue 9, p860 

    Tumors are complex structures of malignant cells and stromal cells that function as an integrated system that promotes tumor progression. Immune cells and other stromal components serve vital cooperative functions that often support tumor growth and metastasis; stromal content and function are...

  • Endobronchial Metastasis from Breast Carcinoma. Pyreddy, Lovdru // Internet Journal of Pulmonary Medicine;2005, Vol. 5 Issue 1, p40 

    Breast cancer is a common malignancy. Lung metastasis to the parenchyma can be seen in 20 to 50% of series. Endobronchial metastasis due to breast carcinoma is a rare finding in these patients and entitles a grim prognosis. Majority of patients have minimal or no pulmonary symptoms. We report a...

  • Cancer Transcriptomics: Modeling metastasis. Ramaswamy, Sridhar // European Journal of Human Genetics;Jan2006, Vol. 14 Issue 1, p1 

    The article comments on the use of microarrays in the identification of genes that may play a role in mediating breast cancer metastasis to the lung. The molecular basis of metastasis is poorly understood due to the complexity of the metastatic phenotype. The use of whole-tumor molecular...

  • Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Yamaki, Sayaka; Fujii, Takaaki; Yajima, Reina; Hirakata, Tomoko; Yamaguchi, Satoru; Fujisawa, Tomomi; Tsutsumi, Soichi; Asao, Takayuki; Yanagita, Yasuhiro; Iijima, Misa; Kuwano, Hiroyuki // Surgery Today;Aug2013, Vol. 43 Issue 8, p901 

    Purpose: Galectin-3 expression is modulated in cancer cells, and that finding has led to the recognition of galectin-3 as a diagnostic or prognostic marker for various cancers, including breast cancer. This study investigated the correlation between galectin-3 expression and the...

  • Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Zavagno, Giorgio; Carcoforo, Paolo; Marconato, Renato; Franchini, Zeno; Scalco, Giuliano; Burelli, Paolo; Pietrarota, Paolo; Lise, Mario; Mencarelli, Roberto; Capitanio, Giovanni; Ballarin, Andrea; Pierobon, Maria Elena; Marconato, Giorgia; Nitti, Donato // BMC Cancer;2005, Vol. 5, p28 

    Background: Sentinel lymph node (SLN) biopsy is an effective tool for axillary staging in patients with invasive breast cancer. This procedure has been recently proposed as part of the treatment for patients with ductal carcinoma in situ (DCIS), because cases of undetected invasive foci and...

  • Metadherin Mediates Lipopolysaccharide-Induced Migration and Invasion of Breast Cancer Cells. Yuhan Zhao; Xiaoli Kong; Xiaoyan Li; Shi Yan; Cunzhong Yuan; Wenwei Hu; Qifeng Yang // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Background Breast cancer is the most prevalent cancer in women worldwide and metastatic breast cancer has very poor prognosis. Inflammation has been implicated in migration and metastasis of breast cancer, although the exact molecular mechanism remains elusive. Principal Findings We show that...

  • Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. Cuk, Katarina; Zucknick, Manuela; Madhavan, Dharanija; Schott, Sarah; Golatta, Michael; Heil, Jörg; Marmé, Frederik; Turchinovich, Andrey; Sinn, Peter; Sohn, Christof; Junkermann, Hans; Schneeweiss, Andreas; Burwinkel, Barbara // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Over the last few years, circulating microRNAs (miRNAs) have emerged as promising novel and minimally invasive markers for various diseases, including cancer. We already showed that certain miRNAs are deregulated in the plasma of breast cancer patients when compared to healthy women. Herein we...

  • Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism. Schoellhammer, Hans F.; Hsu, Felicia; Vito, Courtney; Peiguo Chu; Park, Jinha; Waisman, James; Kim, Joseph // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic...

  • Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.  // BMC Research Notes;2012, Vol. 5 Issue 1, p162 

    The article presents an observational study, that investigates clinical features, treatment and prognosis associated with Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer (MBC), in Morocco. HER2 refers to the human epidermal growth factor receptor....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics